Prime-and-pull vaccine may offer lasting genital herpes protection
A novel vaccine approach may soon offer long-term protection against genital herpes
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Researchers are developing a prime-and-pull vaccine strategy to combat genital herpes. This method aims to enhance the immune response against HSV-2, the virus responsible for most genital herpes cases.
Coverage from UC Irvine News, Inside Precision Medicine, News-Medical, Yale School of Medicine, and Medical Xpress highlights the potential of this approach. The prime-and-pull strategy involves priming the immune system and then pulling immune cells to the site of infection.
Researchers are also exploring the use of mucosal adjuvants to boost immunity. The next steps involve further clinical trials and securing additional funding to advance the vaccine to market.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
What is the prime-and-pull vaccine strategy?
The prime-and-pull vaccine strategy involves priming the immune system to recognize the herpes virus and then pulling immune cells to the site of infection to enhance the body's defense against HSV-2.
Which virus causes most genital herpes cases?
HSV-2 is the virus responsible for most genital herpes cases.
What is a mucosal adjuvant?
A mucosal adjuvant is a substance that enhances the immune response when administered via mucosal surfaces, such as the lining of the nose or mouth.
Coverage (5)
- Immunology researcher secures nearly $4 million NIH grant to advance therapeutic vaccine to help end genital herpes UC Irvine News · 1d ago
- Improving HSV-2 Vaccine Efficacy with Combination Strategy Inside Precision Medicine · 1d ago
- Prime and pull vaccine approach prevents genital herpes infection News-Medical · 1d ago
- Mucosal Adjuvant Boosts Immunity Against Genital Herpes Yale School of Medicine · 1d ago
- Prime-and-pull vaccine may offer lasting genital herpes protection Medical Xpress · 1d ago
Topics
Related trends
Covid vaccine study the acting CDC director blocked is published in an outside journal
A controversial COVID-19 vaccine study blocked by the CDC has been published in an external journal.
COVID Vaccine Linked to New Side Effect, Especially in Older Adults
New COVID vaccine side effect reported, particularly in older adults, as studies reveal cardiovascular benefits
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie is expanding its immunology portfolio through a nearly $11 billion acquisition of Apogee Therapeutics.